Medicenna – Unlocking IL-2 and Other Cytokines’ Immunotherapy Efficacy with Optimized Selectivity, Dosing, and Safety

MDNA.TO (TSX – Canada), MDNAF (OTCQB – USA) Medicenna is a clinical-stage immunotherapy company developing novel, selective IL-2, IL-4, and IL-13 Superkine molecules exclusively in-licensed from Stanford University. The Superkines are engineered versions of naturally circulating immune system cytokines, designed to enhance cancer-killing properties of immune cells while enabling systemic therapeutic dosing by minimizing their […]

September 7th Biotech Update

I do not think things are as dire as they may feel in the sector.  Obviously, if the broader markets weaken (and this is traditionally a weak month), then the sector will not be able to withstand it.  If you squint your eyes just right, we have actually moved higher than the previous lower high […]

August 16th Biotech Update

On a broader market perspective nothing much has changed.  We really have no real momentum in either direction but I still think we have a couple of weeks of vacations before people start getting back and volume returns and we get a clearer picture of the sector sentiment or how it is going to developed […]

July 3rd Biotech Update

We at least ended the week well and while there is not a long weekend, we have the day off tomorrow for the 4th of July.  I think it is going to be a slow news week and nothing too exciting in the markets.  That does not mean that we cannot have a meaningful week, […]

February 15th Biotech Update

It is not the best start so far to the week but it certainly is not bad. We still have the chance to rally and I am a little encouraged by the market reaction to the hotter than expected CPI numbers.  It seems to me more signals that inflation and the Fed are losing their […]

January 3rd Biotech Update

It is a New Year and two paths diverge in the sector.  One would be an unprecedented third year in a row of decline and the second would be the first up year after back to back declines.  I am going to use the next couple days to delineate my predictions for 2023.   LLY […]

November 15th Biotech Update

We had a nice little continuation yesterday and I would not be surprised if we do not run into a pause that refreshes (or at least it would be healthy to do so).  There are a couple of different ways to think about the recent move.  I would lean towards the focus on the Fed […]

June 14th Biotech Update

The market is a mess.  We had treasuries invert on Friday, which is a favorite signal of an impending recession.  To be fair the treasury inversion over predicts recessions and so there have been many instances where nothing happened after an inversion.  All that being said rising rates and high inflation is probably bound to […]

December 22nd Biotech Update

It seems to me that the sector is settling into a lull with the markets as we get to Christmas and then New Years.  We managed to get out a small rally yesterday and have the chance to do it again today as we start red.  While I would like to see more momentum to […]

December 6th Biotech Update

We started lower this morning which is not that bad.  I think if we rallied off the start then we likely give it up but a dip to flush out the frustrated traders (and let us be honest that is all of us at this point) might clear the deck for a really rally later […]

June 8th Biotech Update

So I sort of missed a lot but not really.  Obviously I was driving as the biggest binary in recent memory dropped but ASCO was pretty uneventful and the sector is basically still in the same range as when I left.  I would hope that the BIIB news will at least get the sector to […]

Perimeter Medical Imaging AI Update – Thesis advancing to fruition

Perimeter Medical Imaging AI (PINK.v, PYNKF) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients […]

March 22nd Biotech Update

A more rigorous FDA.  Rising interest rates.  Rising COVID cases in the EU.  Lack of M&A.  A lot of clinical trial failures.  These are the list (probably not comprehensive) of the risks that have been used to explain the selloff in the sector.  None of these have gone away and yet we still have the […]

March 11th Biotech (and Energy) Update

I think we are clearly in what sort of looks like a bottoming process but one that seems like it will be quite messy.  The sector continues to be unable to generate consistently strong days but at least yesterday ended up not being a disaster.  While continuation would have been great, it did not breakdown […]